Cardiovascular toxicity with cancer chemotherapy

Current Problems in Cardiology

Volumn 21, Issue 4, 1996, Pages 227-286

  Frishman, William H ^a,b   Sung, Helen M ^a,b   Yee, Henry C M ^a,b   Liu, Linda L ^a,b   Einzig, Avi I ^a,b   Dutcher, Janice ^a,b   Keefe, Deborah ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGE; AGED; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CHEMICALLY INDUCED DISORDER; CHILD; COMPARATIVE STUDY; DRUG EFFECT; ELECTROCARDIOGRAPHY; FEMALE; HEART; HEART DISEASE; HUMAN; IMMUNOTHERAPY; INFANT; MALE; PRESCHOOL CHILD; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; TIME;

ADULT; AGE FACTORS; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CHILD; CHILD, PRESCHOOL; ELECTROCARDIOGRAPHY; FEMALE; HEART; HEART DISEASES; HUMANS; IMMUNOTHERAPY; INFANT; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 0030120433     PISSN: 01462806     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0146-2806(96)80011-9     Document Type: Article

References (227)

1. Tan C, Tasaku II. Kou-Ping Y, et al. Daunomycin. an antitumor antibiotic, in the troatmenl of neoplastic disoa.se: clinical evaluation with special reference to childhood leukemia. Cancer 1967:20:333-53.
2. Braverman AC, An I in JH, Plappert XIT. el al. Cyclophosphamide cardiotoxicity in hone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 1991:9:1215-23.
3. Antibiotics: doxorubicin HCl. In: Cada DJ, ed. Drug Facts and Comparisons. 48th ed. St. Louis: Facts & Comparisons. Inc., 1994:2703-5.
4. Alkylaling agents, luisulfnn. In: Cada DJ. ed. Drug Facts and Comparisons. 48th ed. St. Louis: Facts & Comparisons, Inc., 1994:2633-5.
5. Lee CR. Faulds D. Altretamine. Drugs 1995:49:932-53.
6. Donl RC. McColl L 5-Fluorouracil and angina [Letter]. Lancet 1965:1:3478.
7. Tomirotti M. Riundi R. Pulici S, et al. Ischemic cardiomvopathy from cindiaminedichloroplalinum (CDDP). Tumori 1984:70:235-6.
8. Labiauca R. Heretla C. Clerici M. el al. Cardiotoxicity of 5-FU: a study of 1083 patients. Tumori 1982:68:505-10.
9. Cradishar VVJ. Vokes F,K. Schilsky RL, el al. Catastrophic vascular events in patients receiving 5-fluorouracil based chemotherapy [Abstract]. Proc Am Assoc Cancer Res 1990:31:1128.
10. deForni M. Malel-Martino MC. Jaillais P et al. Cardiotoxicity of high dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 1992;10:1795-801.
11. Akhtar SS, Salim KR Bano ZA. Symptomatic cardiotoxicity with high dose 5-fluorouracil infusion: a prospective study. Oncology 1993:50:441-4.
12. Keefe DL, Roistacher N, Pierri MK. Clinical cardiotoxicity of 5-fluorouracil. J Clin Pharmacol 1993:33:1060-70.
13. Rezkella S, Kloner RA, Ensley J, et al. Continuous ambulatory EGG monitoring during fluorouracil therapy: a prospective study. J Clin Oncol 1989;7(4):509-14.
14. Praga C, Beretta G, Labianca R. Cardiac toxicity from antitumor therapy. Oncology 1980;37(1):51-8.
15. Robben NC, Pippas AW, Moore JO. The syndrome of 5-fluorouracil cardiotoxicity. Cancer 1992;71(2):493-509.
16. Pottage A, Holt S, Ludgate S, et al. Fluorouracil cardiotoxicity. BMJ 1978;1:547.
17. Ensley J, Patel B, Kloner RA, et al. Clinical syndrome of 5-fluorouracil cardiotoxicity. Invest New Drugs 1989;7:101-9.
18. Freeman NJ, Costanza ME. 5-Fluorouracil associated cardiotoxicity. Cancer 1988:61:36-45.
19. Kleiman NS, Lehane DE, Geyer CE, et al. Prinzmetal's angina during 5fluorouracil chemotherapy. Am J Med 1987:82:566-8.
20. Patel B, Kloner RA, Ensley J, et al. 5-Fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilators. Am J Med Sei 1987;294:238-43.
21. Burger AJ, Mannino S. 5-Fluorouracil-induced coronary vasospasm. Am Heart J 1987;114:433-6.
22. Baker WP, Dainer R Lester WM, et al. Ischemic chest pain after 5-fluorouracil therapy for cancer. Am J Cardiol 1986:57:497-8.
23. Mossed M, Fingert HJ, Varticovski L, Chokshi SK, Isner JM. In vitro evidence that myocardial ischemic resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res 1993;53(13):3028-33.
24. Kuzel T, Esparaz B, Green D, et al. Thrombogenicity of the intravenous 5fluorouracil alone or in combination with cisplatin. Cancer 1990:65:885-9.
25. Riella AR, Kimball JC, Patterson RB. 5-FU cardiotoxicity. Cancer Treat Rep 1981:65:1123-5.
26. McKendall GR, Shurman A, Anamur M, et al. Toxic cardiogenic shock associated with infusion of 5-fluorouracil. Am Heart J 1989:118:184-6.
27. Collins C, Weiden PL. Cardiotoxicity of 5-fluorouracil. Cancer Treat Rep 1987:71:733-6.
28. Haskel CM. Drugs used in cancer chemotherapy. In: Haskel CM, ed. Cancer treatment. 2nd ed. Philadelphia: WB Saunders, 1984:43-106.
29. Chaudari S, Song SYT, Jaski BE. Profound yet reversible heart failure secondary to 5-fluorouracil. Am J Med 1988:85:454-6.
30. Matsubara I, Kamiya J, Imai S. Cardiotoxic effects of 5-fluorouracil in the guinea pig. Jpn J Pharmacol 1980:30:871-9.
31. Stevenson DL, Mikhailidis DR Gillett DS. Cardiotoxicity of 5-fluorouracil. Lancet 1977;2:406-7.
32. Lemaire L, Malet-Martino MC, deForni M, et al. Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug. Br J Cancer 1992:66:119-27.
33. Lemaire L, Malet-Martino MC, Longo S, et al. Fluoroacetaldehyde as cardiotoxic impurity in fluorouracil [Letter]. Lancet 1991;337(8740):560.
34. Henriksson P, Johansson SE. Prediction of cardiovascular complications in patients with prostatic cancer treated with estrogen. Am J Epidemiol 1987;125(6):970-8.
35. Plowman PN. Tamoxifen as adjuvant therapy in breast cancer: current status. Drugs 1993;4G(5):819-33.
36. Weiss RB, Tormey DC, Holland JF, et al. Venous thrombosis during multimodal treatment of primary breast carcinoma. Cancer Treat Rep 1981:65:677-9.
37. Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer therapy in women with stage II breast cancer. N Engl J Med 1988:1318:4047.
38. Goodnough ET. Ilidehiko A, Manni A. et al. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five drug chemotherapy regimen. Cancer 1984:54:1264-8.
39. Sack GH, Eevin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiological. and therapeutic features. Medicine 1977:56:1-37.
40. Saphner T, Tormey DC, Gray R. Venous arid arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991:9(2):286-94.
41. Rutqvist EE, Mattson A. Cardiac and thromboembolic morbidity among postmenopausal women with early stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 1993;85(17):1398-406.
42. Enck RE. Rios CM. Tamoxifen treatment of metastatic breast cancer and antithrombin III levels. Cancer 1984:53:2607-9.
43. Fagerhol MK. Abildgaard U. Bergsjo V, Jacobsen JH. Oral contraceptives and low antithrombin II concentrations [Letter]. Lancet 1970:1:1175.
44. Auger MJ. Mackie MJ. Effects of tamoxifen on blood coagulation. Cancer 1988:61:1316-9.
45. Rossner S. Wallgren A. Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 1984:52:339-46.
46. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tnmoxilen trials: the Scottish Breast Cancer Committee. BMJ 1991:303:435-7.
47. Frishman WH. Herman MP Mitchell J, Lazar J. Other medical approaches for managing hyperlipidemia: past, present, and future. In: Frishman WH, ed. Medical Management of Lipid Disorders: Focus on Prevention ol Coronary Artery Disease. Mt. Kisco. NY: Futura, 1992:227-50.
48. Schwartz J, Freeman R. Frishman WH. Clinical pharmacology ol estrogens: focus on their cardiovascular actions and cardioprotective benefits of replacement therapy in postmenopausal women. J Clin Pharmacol 1995:35:314-29.
49. Losordo DW, Kearney M. Kim EA. et al. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation 1994:89:1501-10.
50. Gangar KE Vyas S, Whitehead M, et al. Pulsatility index in internal carotid artery in relation to transdermal estradiol and time since menopause. Lancet 1991:338:839-42.
51. DeZiegler D. Bessis R, Frydman R. Vascular resistance of uterine arteries: physiological effects ol estradiol and progesterone. Fertil Steril 1991;55:775-9.
52. Kenyon J, ed. Cyproterone in the treatment of men with advanced prostate cancer. Drugs flier Perspect Rational Drug Sel Use 1994:4(10):1-4.
53. Moflat LE. Comparison of Zoladex. diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer. Eur Urol 1990:18(3):26-7.
54. de Voogt HJ, Smith PH, Pavone-Macaluso M, et al. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761, 30762. J Urol 1986;135:303-7.
55. Pavone-Macaluso M, de Voogt HJ, Viggiano G, et al. Comparison of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate in the treatment of advanced prostate cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J Urol 1986;136:624-31.
56. Sundstrup B. Raynaud's phenomenon after bleomycin treatment [Letter]. Med J Aust 1978;2:266.
57. Adoue D, Arlet E Bleomycin and Raynaud's phenomenon [Letter]. Ann Intern Med 1984;100:770.
58. Malcom D. Bleomycin induced injury to the hands. J Med Soc N J 1978;75:314-6.
59. Edwards GS. Long-term treatment with cis-dichlorodiamine-platinumvinblastine-bleomycin: possible association with severe coronary artery disease. Cancer Treat Rep 1979;63:551-2.
60. Adoue D, Arlet P, Vilain C, et al. Raynaud's phenomenon after chemotherapy: apropos of 3 cases. Ann Dermatol Venereol 1985:112:151-5.
61. Antibiotics, pentostatin. In: Cada DJ, ed. Drug Facts & Comparisons. 48th ed. St. Louis: Facts & Comparisions, Inc., 1994:2693-7.
62. Doroshow JH. Doxorubicin-induced cardiac toxicity. N Engl J Med 1991:324:843-5.
63. Praga C, Beretta G, Vigo PL, et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep 1979:63:827-34.
64. Bristow MR, Thompson PD, Martin RP, et al. Early anthracycline cardiotoxicity. Am J Med 1978:65:823-32.
65. Bristow MR, Mason JW, Billingham ME, et al. Doxorubicin cardiomyopathy: evaluation of phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med 1978:88:168-75.
66. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979:91:710-7.
67. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332:1738-43.
68. Young RC, Ozols RE Myers CE. The anthracycline antineoplastic drugs. N Engl J Med 1981:305:159-63.
69. Billingham ME, Mason JW, Bristow MR, et al. Anthracycline cardiomyopathy monitored by morphological changes. Cancer Treat Rep 1978:62:865-72.
70. Blum RH, Carter SK. Adriamycin: a new anticancer drug with significant clinical activity. Ann Intern Med 1974:80:249-59.
71. Torti FM, Bristow MR, Lum BL, et al. Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res 1986:46:3722-7.
72. Moreg JS, Oylon DJ. Outcomes of clinical congestive heart failure induced by anthracycline chemotherapy. Cancer 1992;70:2637-41.
73. Mushlin PS, Oison RD. Anthracycline cardiotoxicity. New Insights Rational Drug Ther 1988;12:1-8.
74. Basser RL, Green MD. Complications of treatment: strategies for prevention of anthracycline cardiotoxicity. Cancer Treat Rev 1993;19:57-77.
75. Billingham ME, Bristow MR. Evaluation of anthracycline cardiotoxicity: predictive ability and functional correlation ot endoinyocardial biopsy. In: Wittes RE, ed. Proceedings ol the Workshop on Mitoxantrone Cardiotoxicity and the Workshop on Clinical Evaluation ol Anthracycline Cardiotoxicitv. Cancer Treatment Symposia. NIH Publication #04-2090. Washington. DC: Government Printing Office. 1084:3:71-6.
76. Schwartz RG. McKenzie WB, Alexander J. et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: seven year experience using radionuclide angiocardiography. Am J Med 1987;82:1109-18.
77. Lipshultz SE, Colan SD. Gelber KD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991;324(12):808-15.
78. Doroshow JH, Akman S, Chu F-F, et al. Rule of the glutathione-glutathione peroxidase cycle in the cytotoxicity of the anticancer cJuinones. Pharmacol Ther 1990:47:359-70.
79. Oison RD. Mushlin PS. Doxorubicin cardiotoxicily: analysis of prevailing hypotheses. FASFB [ 1990:4:3076-86.
80. Doroshow JH. Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J din Invest 1980:65:128-35.
81. Mimnaugh EG. Cram TE, Trush MA. Stimulation of mouse heart and liver microsomal lipid peroxidation by anthracycline drugs: characterization and effects of reactive oxygen scavengers. J Pharmacol Exp Ther 1983;226:806-16.
82. Bachur NR. Gordon SL. Gee MV. A general mechanism for microsomal activation of quinone anticancer agents to tree radicals. Cancer Res 1978:38:1745-50.
83. Bachur NR, Gordon SL, Gee MV. Anthracycline antibiotic augmentation of microsomal electronic transport and free radical formation. Mol Pharmacol 1978:13:901-10.
84. Mimnaugh EG. Trush MA. Bhatnagar M. et al. Enhancement of reactive oxygen-dependent mitochondrial membrane lipid peroxidation by the anticancer drug Adriamycin. Biochem Pharmacol 1985:34:847-56.
85. Doroshow JH. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 1983:43:460-72.
86. Llesuy SE Milei J, Molina H. et al. Comparison of lipid peroxidation and myocardial damage induced by Adriamycin and 4 -epiadriamycin in mice. Tumori 1985:71:241-9.
87. Myers Civ McGuire WR Liss RH.etal. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977:197:105-7.
88. Gianni L. Zweier L. Levy A. el al. Characterization of the cycle of ironmediated electron transfer from adriamycin to molecular oxygen. I Biol Chem 1985:197:165-7.
89. Gianni L. Vigano L. Lanzi C. et al. Role of daunosamine and hydroxyl acetyl side chain in reaction with iron and lipid peroxidation. J Natl Cancer Inst 1980:80:1104-11.
90. Muindi JR, Sinha BK. Gianni L, et al. Hydroxyl radical production and UNA damage induced by anlhracycline-iron complex. FEBS Lett 1984;172:226-30.
91. Muindi JR. Sinha BK, Gianni L. el al. Thiol-dependHiil DNA damage produced by anthracycline-iron complexes: the structure-activity relationships and molecular mechanisms. Mol Pharmacol 1985:27:356-65.
92. Myers CE. Gianna L, Simone GB, et al. Oxidative destruction of erythrocyto ghost membranes catalyzed by the doxorubicin-iron complex. Biochemistry 1982:21:1707-13.
93. 3+ADP-EDTA systems. Biochim Biophys Acta 1983;753:411-21.
94. 2 reduction by the iron complexes of adriamycin and daunomycin: the importance of side chain hydroxyl group. Biochim Biophys Acta 1986;884:326-36.
95. Doroshow JH, Locker GY, Ifrim I, et al. Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine. J Clin Invest 1981;68:1053-64.
96. Myers C, Bonow R, Palmeri S, et al. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol 1983;10:53-5.
97. Rhoden W, Hasleton R Brooks N. Anthracyclines and the heart. Br Heart J 1993:70:499-502.
98. Waagstein F, Fu LX, Hjalmarson A. A new insight into adriamycin-induced cardiotoxicity. Int J Cardiol 1990:29:15-20.
99. Polverino W, Basso A, Bonelli A, et al. 4-Epidoxorubicin: its cardiotoxicity: possible cardiac protection with gallopamil, a drug with calcium antagonist action. Minerva Cardioangiol 1992:40:23-30.
100. Polsker GL, Faulds D. Epirubicin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 1993;45(5):788-856.
101. Weesner KM, Bledsoe M, Chauvenet A, et al. Exercise echocardiography in the detection of anthracycline cardiotoxicity. Cancer 1991:68:435-8.
102. Klewer SE, Goldberg SJ, Donnerstein RL, et al. Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer. J Am Coll Cardiol 1992:19:394-401.
103. Steinberg JS, Wasserman AG. Radionuclide ventriculography for evaluation and prevention of doxorubicin cardiotoxicity. Clin Ther 1985:7:660-7.
104. Stoddard MF, Seeger J, Liddell NE, et al. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol 1992:20:62-9.
105. Marchandise B, Schroeder E, Bosley A, et al. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 1989:118:92-8.
106. Yamada T, Matsumori A, Tamaki N, et al. Detection of adriamycin cardiotoxicity with indium-Ill labelled antimyosin monoclonal antibody imaging. Jpn Cire J 1991;55:377-83.
107. Bhattacharya S, Lahiri A. Clinical role of indium-111 antimyosin imaging. Eur J Nucl Med 1991:18:889-95.
108. Carrio I, Estorch M, Berna L, et al. Assessment of anthracycline-induced myocardial damage by quantitative indium-Ill myosin-specific monoclonal antibody studies. Eur J Nucl Med 1991;18:806-12.
109. Carrio I, Lopez-Pousa A, Estorch M, et al. Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111 antimyosin monoclonal antibody studies. J Nucl Med 1993:34:1503-7.
110. Lekakis J, Vassilopoulos N, Psichoyiou H, et al. Doxorubicin cardiotoxicity detected by indium-Ill myosin-specific imaging. Eur J Nucl Med 1991;18:225-6.
111. Narula J, Strauss HW, Khaw BA. Antimyosin positivity in doxorubicin cardiotoxicity: earlier than the conventional evidence. J Nucl Med 1993:34:1507-9.
112. 111In monoclonal antimvosin Fab in detecting doxorubicin cardiotoxicity in rats. Circulation 1992:86:1965-72.
113. Valdes-Olmos KA. Ton Bokol-Huinink VV\V. Greve JC, et al. 1-123 MIBC and serial radionuclide angiocardiography in doxorubicin-related cardioloxicity. Clin Nucl Med 1992:17:163-7.
114. 123I-MIBG myocardial SPECT in patients with adriamydn-incluced cardiomyopathv. Jpn J Nucl Med 1994:31:1051-7.
115. 123I BMIPP imaging. Ann Nucl Med 1994:8:177-82.
116. Piwnica-Worms D, Chin ML. Kronauge JE Detection of adriamycin-induced cardiotoxicity in cultured heart colls with technetium 99m-SESTAMIBI. Cancer Chemother Pharmacol 1993:32:385-91.
117. Bauch M, Ester A. Kimura B. et al. Atrial natriuretic peptidc as a marker for doxorubicin-induced c:ardiotoxic effects. Cancer 1992:69:1492-7.
118. Steinherz LLJ, Graham T. Hurwiz R, et al. Guidelines for cardiac monitoring of children during and after anthracvcline therapy: report of the Cardiology Committee of the Children's Cancer Study Group. Pediatrics 1992:89:942-9.
119. Logha SS. Benjamin RS, Makay B, et al. Reduction of doxorubicin cardioloxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982:96:1 13-39.
120. Shapira J, Goft'riod M. Usinier M. et al. Reduced cardiotoxicity of doxorubicin by a six hour infusion regimen. Cancer 1990:65:870-3.
121. Hortobagyi GN. Fryo D. Buzdar AU, et al. Decreased cardiac loxicity of doxorubicin administered by continuous intravenous infusion in combination with chemotherapy for metastatic breast carcinoma. Cancer 1989:63:37-45.
122. Weiss AJ. Metier GE. Fletcher WS. et al. Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat Rep 1976:60:813-22.
123. Speyer JL. Green MD, Dubin N. et al. Prospective evaluation of cardiotoxicity during a six hour doxorubicin infusion regimen in women with adenocarcinoma of the breast. Am J Med 1985:78:555-63.
124. Speyer JL. Green MD. Zeleniuch-Jacquotte A. et al. ICRF-187 permits longer treatmoni with doxorubicin in women with breast cancer. J Clin Oncol 1992:10:117-27.
125. Speyer JL. Green MD, Kramer E. et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancor. N Engl J Med 1988:319:745-52.
126. Herman EH. Ferrans VJ, Young RS. et al. Effect of pretreatment with ICRF187 on the total cumulative dose of doxorubicin tolerated by beagle dogs. Cancer Res 1988:48:6918-25.
127. Herman EH. Ferrans VJ, Myers CE, et al. Comparison of the effectiveness of (±]-1.2-bis(dioxopiparzinyl-l-vl)propane (IGRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicily in beagles. Cancer Res 1985:45 276-81.
128. Herman EH. Ferrans VJ. Amelioration of chronic anthracycline cardiotoxicity by ICRF-187 and other compounds. Cancer Treat Rev 1987:14:225-9.
129. Herman EH, Ferrans VJ, Reduction of chronic doxorubicin cardiotoxicity in dogs by prolreatment with (±)1,2-bis(dioxopiparazinyl-1-yl)propane (ICRF-187). Cancer Res 1981:41:3436-40.
130. Herman EH, Ardalan B, Bier C, et al. Reduction of daunorubicin lethality and myocardial cellular alterations by pretreatment with ICRF-187 in Syrian golden hamsters. Cancer Treat Rev 1979;63:89-92.
131. Weisberg SR, Rosenfeld CS, York RM, et al. Dexrazoxane (ADR 529, ICRF187, Zinecard) protects against doxorubicin induced chronic cardiotoxicity [Abstract]. Proc Am Soc Clin Oncol 1992;11:91.
132. Maillard JA, Speyer JL, Hanson K, et al. Prevention of chronic adriamycin cardiotoxicity with the bis dioxopiperazine dexrazoxane in patients with advanced or metastatic breast cancer [Abstract]. Proc Am Soc Clin Oncol 1992:11:91.
133. Decorti G, Klugmann FB, Candussio L. Characterization of histamine secretion induced by anthracyclines in rat peritoneal mast cells. Biochem Pharmacol 1986:35:1939-41.
134. Klugmann FB, Decorti G, Candussio L. Amelioration of 4-epidoxorubicininduced cardiotoxicity by sodium cromoglycate. Eur J Cancer Clin Oncol 1989:25:361-8.
135. deJong J, Schoofs PR, Underwater RC, et al. Isolated mouse atrium as a model to study anthracycline cardiotoxicity: the role of the betaadrenoceptor system and reactive oxygen species. Res Commun Chem Pathol Pharmacol 1990:68:275-89.
136. Rasmussen IMN, Schou HS, Hermansen K. Cardiotoxic effects and the influence on the β-adrenoceptor function of doxorubicin (Adriamycin) in the rat. Pharmacol Toxicol 1989:65:69-72.
137. Siveski-Iliskovic N, Hill M, Chow DA, Singal PK. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation 1995:91:10-5.
138. Launchbury AP, Habboubi N. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity, and toxicity. Cancer Treat Rev 1993;19:197-228.
139. Bertazzoli C, Rovero C, Ballerini L, et al. Experimental systemic toxicology of 4 epidoxorubicin, a new less cardiotoxic anthracycline antitumour agent. Toxicol Appl Pharmacol 1985;79:412-22.
140. Pouna P Bonoron-Adele S, Gouverneur G, et al. Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin. Cancer Chemother Pharmacol 1995:35:257-61.
141. Alderton PM, Gross J, Green MD. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res 1992:52:194-201.
142. MengozziG, PalagiC, Petronio AS, et al. The evaluation of the cardiotoxicity of 4 epidoxorubicin at high doses. Cardiologia 1991:36:137-42.
143. Lahtinen R, Kuikka J, Nousiainen T, et al. Cardiotoxicity of epirubicin and doxorubicin: a double-blind randomized study. Eur JHaematol 1991;46:3015.
144. Keating MJ. Oral idarubicin in haematological malignancies: putative indications. Clin Drug Invest 1995;9(suppl 2):29-38.
145. Robert J. Pharmacological properties of oral idarubicin. Clin Drug Invest 1995;9(suppl 2):1-8.
146. Twelves CJ. Oral idarubicin in solid tumour chemotherapy. Clin Drug Invest 1995;9(suppl 2):39-54.
147. Case DC. Safety of oral idarubicin. Clin Drug Invest 1995;9(suppl 2):9-15.
148. Pannuti E Farris A, Saccani E Multicenter comparative randomized clinical trial of idarubicin vs adriamycin in the treatment of advanced breast cancer: general report. Internal Report IMI 30/7591. March 1900. and Addendum Al, October 1992. Milan: Farmitalia Carlo Krba, 1992.
149. Penco S. Casazza AM. Franchi G. et al. Synthesis, antitumor activity, and cardiac toxicity of new 4 demethoxy-anlhracyclines. Cancer Treat Rev 1903:67:665-71
150. Massimo L, Contegiacomo A. Vici P et al. A prospective randomized trial ot doxorubicin versus idarubicin in the treatment of advanced breast cancer. Cancer 1909:04:2431-0.
151. Lopez M, Carpano VR Palpaldo P. et al. Randomized trial of doxorubicin versus oral idarubicin in advanced breast carcinoma. In: Berkarda B, ot al., eds. Progress in antimicrobial and anticancer chemotherapy. Istanbul: Ecomed. 1987:435-7.
152. Antibiotics, Idarubicin HCl. In: Cacla DJ, ed. Drugs Facts & Comparisons. 48th ed. St. Louis: Facts & Comparisons. Inc., 1994:2090-702.
153. Broggini M. Ilalia C. Colombo L, et al. Activity and distribution of IV and oral 4-demethoxy daunorubicin in murine experimental tumors. CancelTreat Rev 1904:08:739-47.
154. Boulante V. Ferrari L. Brambilla C, ot al. New anlhracycline analogues in advanced breast cancer. Eu r J Cancer Clin Oncol 1986:22:1379-05.
155. Van Oosterom AT. Mouridsen HT. Wildiers J, et al. Advanced breast cancer: a comparative evaluation ot epirubicin and doxorubicin (adriamycin): preliminary report of the KORTC Ureast Cancer Cooperative Group. Clin Trials J 1987;24(suppl 1):131-7.
156. Perez DJ. Harvey VJ, Robinson BA. et al. A randomized comparison of singleagent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J Clin Oncol 1991:9:2148-52.
157. Brambilla C. Rossi A, Honfante V, et al. Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rep 1986:70:201-0.
158. Antibiotics, mitoxantrone HCl. In: Cada DJ. ed. Drugs Facts & Comparisons. 48th ed. St. Louis: Facts & Compensions. Inc., 1994:2709-12.
159. Mitotic inhibitors, vinblastine sulfate. In: Cada DJ. cd. Drugs Facts & Comparisons. 48lh ed. St. Louis: Facts & Comparisons, Inc., 1994:2729-32.
160. Mitotic inhibitors, podophyllotoxin derivatives. In: Cada DJ. ud. Drugs Facts & Comparisons. 48th ed. St. Louis: Facts & Comparisons, Inc., 1994:2720-5.
161. Isner JM. Dietz. WA. Cardiovascular consequences of recombinant DNA technology: interleukin 2. Ann Intern Med 1988;109(12):933-5.
162. West WH, Tauer KW. Yannell JR. et al. Constant-infusion recombinant interleukin 2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987:316:898-905.
163. Nora B. Belani C. Silverman H, Abrams J. Immunotherapy of advanced cancer [Letter]. N Engl J Med 1987:310:274-0.
164. Rosenberg SA. Lotze MT. Muul LM. et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin 2 or high dose interleukin 2 alone. N Engl J Med 1987:310:889-97.
165. Osanto S. Cluitmans FH. Franks CR. Bosker HA. Cleton FJ. Myocardial injury after interleukin 2 therapy JLetter). Lancet 1988:2(8001):40-9.
166. Margolin KA. Rayner AA. Hawkins MJ, et al. Interloukin 2 and lymphokineactivated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol 1909:7:406-98.
167. Ognibene F P. Rosenberg SA. Lotze M. et al. Interleukin 2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar lu those seen in septic shock. Chest 1909:94:750-4.
168. Gaynor ER, Vitek L, Sticklin L, et al. The hemodynamic effects of treatment with interleukin 2 and lymphocyte activated killer cells. Ann Intern Med 1988:109:953-8.
169. Parker MM, Parrillo JE. Septic shock: hemodynamics and pathogenesis. JAMA 1983:250:3324-7.
170. Lissom P, Barni S, Cattaneo G, et al. Evaluation of the cardiovascular toxicity related to cancer immunotherapy with interleukin 2 by monitoring atrial natriuretic peptide secretion: a case report. Tumor 1990;76:603-5.
171. Du Bois JS, Udelson JE, Atkins MB. Severe reversible global and regional ventricular dysfunction associated with high-dose interleukin-2 immunotherapy. J Immunol 1995;18:119-23.
172. Schecter D, Nagler A. Recombinant interleukin 2 and recombinant interferon immunotherapy cardiovascular toxicity. Am Heart J 1992;123:1736-9.
173. McGowan FX, Takeuchi K, del Nido PJ, et al. Myocardial effects of interleukin 2. Transplant Proc 1994;26:209-10.
174. Nora R, Abrams JS, Tait NS, et al. Myocardial toxic effects during recombinant interleukin 2 therapy. J Natl Cancer Inst 1989:81:59-63.
175. Lee RE, Lotze MT, Skibber JM, et al. Cardiorespiratory effects during recombinant interleukin 2. J Clin Oncol 1989;7:7-20.
176. Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use of high dose interleukin 2 in the treatment of 652 patients with cancer. Ann Surg 1989:210:474-85.
177. Kragel AH, Travis WD, Steig RG, et al. Myocarditis or acute myocardial infarction associated with interleukin 2 therapy for cancer. Cancer 1990:66:1513-6.
178. Miscellaneous antineoplastics, Aldesleukin (interleukin-2). In: Cada DJ, ed. Drugs Facts & Comparisons. 48th ed. St. Louis: Facts & Comparisons, Inc., 1994:2772-9.
179. Kragel AH, Travis WD, Feinberg L, et al. Pathologie findings associated with interleukin-2 based immunotherapy for cancer: a postmortem study of 19 patients. Hum Pathol 1990:21:493-502.
180. Samlowski WE, Ward JH, Craven CM, et al. Severe myocarditis following highdose interleukin-2 administration. Arch Pathol Lab Med 1989:113:838-41.
181. Schuchter LM, Hendricks CB, Holland RH, et al. Eosinophilic myocarditis associated with high dose interleukin 2 therapy. Am J Med 1990:88:439-40.
182. Herberman RB. Effects of biological response modifiers on effector cells with cytotoxic activity against tumors. Semin Oncol 1986:13:195-9.
183. Matsumori A, Crumpacker CS, Abelmann WH. Prevention of viral myocarditis with recombinant human leukocyte interferon alpha A/D in a murine model. J Am Coll Cardiol 1987;9:1320-5.
184. Matsumori A, Kawai C, Crumpacker CS, et al. Pathogenesis and preventive and therapeutic trials in an animal model of dilated cardiomyopathy induced by a virus. Jpn Cire J 1987;51:661-4.
185. Matsumori A, Tomioka N, Kawai C. Protective effect of recombinant alpha interferon on coxsackievirus B3 myocarditis in mice. Am Heart J 1988:115:1229-32.
186. Oldham RR. Toxic effects of interferon. Science 1982;219:902.
187. Kirkwood JM, Ernstoff MS, Davis CS, et al. Comparison of intramuscular and intravenous recombinant alpha 2 interferon in melanoma and other cancers. Ann Intern Med 1985;103:32-6.
188. Martino S, Ratanatharathorn V, Karanes C, et al. Reversible arrhythmias observed in patients treated with recombinant alpha 2 interferon. J Cancer Res Clin Oncol 1987:113:376-8.
189. Cohen MC, Huberman MS. Nesto RW. Recombinant alpha 2 interleronrelated cardiomyopathy. Am J Med 1988:85:549-51.
190. Quesada JR, Talpaz M, Rios A. et al. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986:5:234-43.
191. Sonnenblick M, Rosin A. Cardiotoxicity of Interferon: a review of 44 cases. Chest 1991:99:557-61.
192. Kenyon J, ed. Faclitaxel: a promising addition to the antinooplastic armamentarium. Drugs Thor Perspect Rational Drug Sel Use 1995:5(3):1-5.
193. Rowinsky EK, Cilbert MR, McCuire WR et al. Sequences of taxol and cisplatin: a phase 1 and pharmacologie study. J Clin Oncol 1991:9:1692-703.
194. Eisenhauer EA. ten Bokkel Huinink WW. Swenerton KD. et al. EuropeanCanadian randomized trial of paclitaxel in relapsed ovarian cancer: highdose vs low-dose and long vs short infusion. J Clin Oncol 1994:12:2654-66.
195. McCuiro WR Rowinsky EK, Rosenshein NB. et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial leoplasms. Ann Intern Med 1989:111:273-9.
196. Sarosy C, Kohn K, Stone DA, et al. Phase 1 study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 1992:10:1165-70.
197. Biadi O, Mengozzi G. Cherarducci C, et al. Evaluation of taxol cardiotoxicity in metastatic breast cancer. Ann N Y Acad Sci 1993:698:403-5.
198. Gibbs H. Ewer M. Holmes F, et al. Cardiac: monitoring during administration of taxol-doxorubicin chemotherapy in patients with metastatic breast cancer: a preliminary report [Abstract]. Proc Am Soc Clin Oncol 1992:11:86.
199. Miscellaneous anlineoplaslics, paclitaxel. In: Cada DJ, ed. Drugs Facts & Comparisons. 48th ed. St. Eouis: Facts & Comparisons, Inc., 1994:2780-5.
200. Donehower RC. Rowinsky EK. An overview of experience with Taxol (paclitaxel) in the USA. Cancer Treat Rev 1993;19(suppl C):63-78.
201. Rogers BB. Taxol: a promising new drug of the 90s. Oncol Nurs Forum 1993;20(10):1483-9.
202. Pazdur R, Kudelka AR Kavanagh JJ, Cohen PR, Raher MN. The laxoids: paclitaxel (Taxol) and docetaxel (Taxotore). Cancer Treat Rev 1993:19:351-86.
203. Loronx W, Reimann HJ, Schmal A. et al. Hislamine release in dogs by
204. Arbuck SC. Adams I, Strauss H, et al. A reassessment of cardiac toxicity associated with Taxol [Abstract]. Second National Cancer Institute Workshop on Taxol and Taxus, September 23, 24. 1992, Alexandria, Va.
205. Walker FE. Paclitaxel (Taxol): side effects and patient education issues. Semin Oncol Nurs 1993:9(4. suppl 2):6-10.
206. Bristol-Myers Squibb. Taxol administration guide. Princeton, NJ: BristolMyers Squibb. 1993.
207. Roth BJ. Yeap BY. Wilding C. et al. Taxol in advanced, hormone-refractory carcinoma of the prostate: a phase II trial of the Eastern Cooperative Oncology Group. Cancer 1993:72:2457-60.
208. Brown T. Tangen C, Fleming T, et al. A phase II trial of taxol and granulocyte colony stimulating factor (C-CSF) in patients with adenocarcinoma of the pancreas [Abstract]. Proc Am Soc Clin Oncol 1993:12:200.
209. Chang AY, Kini k, Click J. et al. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Croup results. J Natl Cancer lust 1993:85:388-94.
210. Kohn EC, Sarosy C., Bicher A, el al. Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 1994:86:18-24.
211. Nakashima L. A review of taxol: highlights on antineoplastic drugs [Monograph]. Princeton, NJ: Bristol-Myers Squibb, 1992.
212. Gianni L, Straneo M, Capril G, et al. Optimal dose and sequence finding study of paclitaxel (P) by 3 h infusion combined with bolus doxorubicin (D) in untreated metastatic breast cancer patients (pts) [Abstract]. Proc Am Soc Clin Oncol 1994:13:74.
213. Rowinsky EK, Onetto N, Canetta R, et al. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 1992;19:646-62.
214. Holmes FA, Walters RS, Theriault RL, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991;83:1797-805.
215. Sledge G, Sparano J, McCaskill-Stevens W, et al. Pilot trial of alternating Taxol and Adriamycin for metastatic breast cancer [Abstract]. Proc Am Soc Clin Oncol 1993;12:71.
216. Rowinsky EK, Eisenhauer EA, Chaudhry V, et al. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993:20(4 suppl 3):115.
217. Rowinsky EK, McGuire WP, Guarnieri T, et al. Cardiac disturbances during the administration of taxol. J Clin Oncol 1991:9:1704-12.
218. Spencer CM, Faulds D. Paclitaxel: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994:48:794-847.
219. Pazdur R, Newman RA, Newinan BM, et al. Phase I trial of Taxotere: five day schedule. J Natl Cancer Inst 1992:84:1781-8.
220. Burris HA, Irvin R, Kuhn J, et al. Phase I clinical trial of Taxotere given as either a 2-hour or a 6-hour infusion. J Clin Oncol 1993:11:950-8.
221. Extra JM, Rousseau E Bruno R, et al. Phase I and pharmacokinetic study of Taxotere given as a short intravenous infusion. Cancer Res 1993:53:1037-42.
222. de Valeriola D, Brassinne C, Piccart M, et al. Phase I pharmacokinetic study of Taxotere (RP56976) administered as a weekly infusion. Proc ACCR 1992;33:1563.
223. Bissett D, Setanoians A, Cassidy J, et al. Phase I and pharmacokinetic study of Taxotere (RP56976) administered as a 24-hour infusion. Cancer Res 1993:53:523-7.
224. Miscellaneous antineoplastics, procarbazine HCl. In: Cada DJ, ed. Drugs Facts & Comparisons. 48th ed. St. Louis: Facts & Comparisons, Inc., 1994:2786-8.
225. Eli Lilly & Co. Gemcitabine HCl (LY188011 HCl): clinical investigation brochure. Indianapolis: Eli Lilly, October 1993.
226. Eli Lilly & Co. Gemzar (gemcitabine HCl): treatment IND program for patients with pancreatic cancer protocol. Indianapolis: Eli Lilly, December 1994.
227. Doxorubicin (systemic): drug information for the health care professional. 16th ed. Rockville, Md: The U.S. Pharmacopeial Convention Inc., 1996:1305-10.